A precision immune oncology approach, interrogating individual tumor expression patterns of OX40 and OX40L and other immunomodulatory effectors, may warrant exploration in future studies of both single-agent and combination regimens with OX40 agonists. The gene discussed is TNFSF4; the disease is neoplasm.